Jeffrey Sevigny, M.D.
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
March 03, 2025 07:00 ET | Rapport Therapeutics, Inc.
Rapport appoints Dr. Jeffrey Sevigny as CMO, a physician-scientist with more than 15 years of translational and clinical drug development
Rapport_Logo_Color_RGB.png
Rapport Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025 07:00 ET | Rapport Therapeutics, Inc.
Rapport Therapeutics will participate in fireside chats at the upcoming TD Cowen 45th Annual Health Care Conference and Stifel 2025 Virtual CNS Forum.
Rapport_Logo_Color_RGB.png
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025 09:12 ET | Rapport Therapeutics, Inc.
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 09, 2025 07:00 ET | Rapport Therapeutics, Inc.
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
December 06, 2024 12:01 ET | Rapport Therapeutics, Inc.
Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024 07:00 ET | Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline